Back to Browse Journals » Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy » Volume 6

Lorcaserin for weight management

Authors Taylor JR, Dietrich E, Powell J

Published Date June 2013 Volume 2013:6 Pages 209—216


Received 19 April 2013, Accepted 10 May 2013, Published 13 June 2013

James R Taylor, Eric Dietrich, Jason Powell

University of Florida College of Pharmacy, Department of Pharmacotherapy and Translational Research, Gainesville, FL, USA

Abstract: Type 2 diabetes and obesity commonly occur together. Obesity contributes to insulin resistance, a main cause of type 2 diabetes. Modest weight loss reduces glucose, lipids, blood pressure, need for medications, and cardiovascular risk. A number of approaches can be used to achieve weight loss, including lifestyle modification, surgery, and medication. Lorcaserin, a novel antiobesity agent, affects central serotonin subtype 2A receptors, resulting in decreased food intake and increased satiety. It has been studied in obese patients with type 2 diabetes and results in an approximately 5.5 kg weight loss, on average, when used for one year. Headache, back pain, nasopharyngitis, and nausea were the most common adverse effects noted with lorcaserin. Hypoglycemia was more common in the lorcaserin groups in the clinical trials, but none of the episodes were categorized as severe. Based on the results of these studies, lorcaserin was approved at a dose of 10 mg twice daily in patients with a body mass index ≥30 kg/m2 or ≥27 kg/m2 with at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus, or dyslipidemia, in addition to a reduced calorie diet and increased physical activity. Lorcaserin is effective for weight loss in obese patients with and without type 2 diabetes, although its specific role in the management of obesity is unclear at this time. This paper reviews the clinical trials of lorcaserin, its use from the patient perspective, and its potential role in the treatment of obesity.

Keywords: lorcaserin, obesity, diabetes

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at:

Other article by this author:

Readers of this article also read:

Management of limited joint mobility in diabetic patients

Abate M, Schiavone C, Salini V, Andia I

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2013, 6:197-207

Published Date: 7 May 2013

Treatment outcomes after initiation of exenatide twice daily or insulin in clinical practice: 12-month results from CHOICE in six European countries

Ostenson CG, Matthaei S, Reaney M, Krarup T, Guerci B, Kiljanski J, Salaun-Martin C, Sapin H, Bruhn D, Mathieu C, Theodorakis M

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2013, 6:171-185

Published Date: 26 April 2013

Prevalence of overweight and obesity in adult Nigerians – a systematic review

Chukwuonye II, Chuku A, John C, Ohagwu KA, Imoh ME, Isa SE, Ogah OS, Oviasu E

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2013, 6:43-47

Published Date: 22 January 2013